U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07391215) titled '5G-PEARL: Paxalisib in Malignant Brain Tumours' on Oct. 05, 2023.
Brief Summary: The purpose of this clinical trial is to evaluate the safety and tolerability of paxalisib in combination with temozolomide and to determine the preliminary antitumour activity of the combination therapy. In the Phase 1b of this study parallel biomarker defined arms will be opened in the front-line unmethylated MGMT setting, enrolling 10 patients onto each arm. These patients will be treated with paxalisib in combination with temozolomide (TMZ). The starting dose of paxalisib will be 45mg once a day (OD) with the option of increasing to 60 mg (30 mg BD) ...